Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.

Lin G, Pankuch GA, Appelbaum PC, Kosowska-Shick K.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):287-9. doi: 10.1016/j.diagmicrobio.2012.04.003. Epub 2012 May 8.

PMID:
22575272
2.

In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

McGhee P, Clark C, Credito K, Beachel L, Pankuch GA, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2417-9. doi: 10.1128/AAC.01672-10. Epub 2011 Feb 22.

3.

Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.

Pankuch GA, Lin G, Kubo A, Armstrong ES, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.

4.

Time-kill activity of the streptogramin NXL 103 against Gram-positive and -negative bacteria.

Pankuch GA, Lin G, Clark C, Appelbaum PC.

Antimicrob Agents Chemother. 2011 Apr;55(4):1787-91. doi: 10.1128/AAC.01159-10. Epub 2011 Jan 18.

5.

Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Pankuch GA, Seifert H, Appelbaum PC.

Diagn Microbiol Infect Dis. 2010 Jun;67(2):191-7. doi: 10.1016/j.diagmicrobio.2010.01.004. Epub 2010 Mar 24.

PMID:
20338710
6.

Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Lin G, Pankuch GA, Ednie LM, Appelbaum PC.

Antimicrob Agents Chemother. 2010 May;54(5):2201-5. doi: 10.1128/AAC.01143-09. Epub 2010 Feb 16.

7.

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.

8.

Postantibiotic effect of ceftaroline against gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Oct;53(10):4537-9. doi: 10.1128/AAC.00785-09.

9.

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.

Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.

10.

Postantibiotic effects of telavancin against 16 gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Mar;53(3):1275-7. doi: 10.1128/AAC.01244-08. Epub 2009 Jan 5.

11.

Postantibiotic effect of tigecycline against 14 gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2009 Feb;53(2):782-4. doi: 10.1128/AAC.01122-08. Epub 2008 Dec 8.

12.

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Pankuch GA, Lin G, Seifert H, Appelbaum PC.

Antimicrob Agents Chemother. 2008 Jan;52(1):333-6. Epub 2007 Oct 29.

13.

Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.

Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC.

Antimicrob Agents Chemother. 2007 Feb;51(2):770-3. Epub 2006 Nov 20.

14.

Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Nov;50(11):3956-8.

15.

Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.

Pankuch GA, Hoellman D, Bryskier A, Lowther J, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Nov;50(11):3914-6.

16.

Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Bogdanovich T, Smith KA, Clark C, Pankuch GA, Lin G, McGhee P, Dewasse B, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Jul;50(7):2323-9.

17.

Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, Dewasse B, Choi DR, Ryu JM, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71.

18.

Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Pankuch GA, Lin G, Hoellman DB, Good CE, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2006 May;50(5):1727-30.

19.
20.
21.

Postantibiotic effect of DX-619 against 16 gram-positive organisms.

Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Sep;49(9):3963-5.

22.

Activity of the new quinolone WCK 771 against pneumococci.

Appelbaum PC, Pankuch GA, Bozdogan B, Lin G, Jacobs MR, Patel MV, Gupte SV, Jafri MA, De Souza NJ, Khorakiwala HF.

Clin Microbiol Infect. 2005 Jan;11(1):9-14.

23.

Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.

Kosowska K, Credito K, Pankuch GA, Hoellman D, Lin G, Clark C, Dewasse B, McGhee P, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4113-9.

24.

Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Matic V, Kosowska K, Bozdogan B, Kelly LM, Smith K, Ednie LM, Lin G, Credito KL, Clark CL, McGhee P, Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12.

25.

Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Hoellman DB, Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Oct;48(10):4037-9.

26.
27.

Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Pankuch GA, Kelly LM, Lin G, Bryskier A, Couturier C, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Oct;47(10):3270-4.

28.

Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.

Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Sep;47(9):3012-4.

29.

Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.

Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2003 Mar;47(3):1140-2.

30.

Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

Pankuch GA, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2003 Feb;51(2):443-6.

PMID:
12562720
31.

Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.

Pankuch GA, Bozdogan B, Nagai K, Tambić-Andrasević A, Schoenwald S, Tambić T, Kalenić S, Plesko S, Tepes NK, Kotarski Z, Payerl-Pal M, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Aug;46(8):2671-5.

32.

Activity of cefditoren against respiratory pathogens.

Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2002 Jul;50(1):33-41.

PMID:
12096004
33.

Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Pankuch GA, Nagai K, Davies TA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Jan;46(1):251-4.

34.

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2002 Jan;46(1):42-6.

35.

Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.

Credito KL, Lin G, Pankuch GA, Bajaksouzian S, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2001 Jan;45(1):67-72.

36.

In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.

Nagai K, Davies TA, Dewasse BE, Pankuch GA, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 2000 Dec;46(6):909-15.

PMID:
11102409
37.

In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Nagai K, Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6.

38.

Antipneumococcal activity of ABT-773 compared to those of 10 other agents.

Davies TA, Ednie LM, Hoellman DM, Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2000 Jul;44(7):1894-9.

39.
40.

Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2000 Feb;44(2):304-10.

41.

Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics.

Pankuch GA, Hoellman DB, Jacobs MR, Appelbaum PC.

J Antimicrob Chemother. 1999 Sep;44(3):381-4.

PMID:
10511406
42.

Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1999 Oct;43(10):2574-5.

43.

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC.

Antimicrob Agents Chemother. 1999 Aug;43(8):1901-8.

44.

In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1999 May;43(5):1177-82.

45.

Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.

Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 Nov;42(11):3032-4.

46.
47.

In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Pankuch GA, Jueneman SA, Davies TA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 Nov;42(11):2914-8.

48.

Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 Jun;42(6):1503-5.

49.

Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.

Pankuch GA, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 1998 May;42(5):1263-5.

Supplemental Content

Loading ...
Support Center